Quick Answer
Vitamin K Bone Turnover Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: The study used the Jadad scale and Cochrane Risk of Bias and GRADE criteria to evaluate study quality while the researchers used funnel plots and Egger's test to assess publication bias.
Key Takeaways
- 01The study used the Jadad scale and Cochrane Risk of Bias and GRADE criteria to evaluate study quality while the researchers used funnel plots and Egger's test to assess publication bias. [Lv C (2026)]
- 02Results Interventions significantly improved BMD (SMD = 0.47; 95% CI: 0.31-0.62; p 2 = 79%), bone turnover markers (SMD = -0.69; 95% CI: -1.17 to -0.20; p = 0.004; I 2 = 99%), inflammation/oxidative stress markers (SMD = -1.34; 95% CI: -1.45 to -1.23; p 2 = 0%), and postoperative recovery/metabolic outcomes (SMD = -2.04; 95% CI: -2.31 to -1.77; p 2 = 86%). [Lv C (2026)]
- 03Conclusion The study results demonstrate that nutritional and therapeutic treatments lead to better bone density results together with improved biochemical markers and reduced inflammation and faster recovery after surgery. [Lv C (2026)]
- 04Background Nutritional and therapeutic methods are used to enhance bone health and assist in fracture healing while improving functional ability and reducing inflammation and bettering surgical results. [Lv C (2026)]
The current Migaku evidence database contains 2 reusable source documents for Vitamin K Bone Turnover Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- The study used the Jadad scale and Cochrane Risk of Bias and GRADE criteria to evaluate study quality while the researchers used funnel plots and Egger's test to assess publication bias. [Lv C (2026); evidence level 1]
- Results Interventions significantly improved BMD (SMD = 0.47; 95% CI: 0.31-0.62; p 2 = 79%), bone turnover markers (SMD = -0.69; 95% CI: -1.17 to -0.20; p = 0.004; I 2 = 99%), inflammation/oxidative stress markers (SMD = -1.34; 95% CI: -1.45 to -1.23; p 2 = 0%), and postoperative recovery/metabolic outcomes (SMD = -2.04; 95% CI: -2.31 to -1.77; p 2 = 86%). [Lv C (2026); evidence level 1]
- Conclusion The study results demonstrate that nutritional and therapeutic treatments lead to better bone density results together with improved biochemical markers and reduced inflammation and faster recovery after surgery. [Lv C (2026); evidence level 1]
- Background Nutritional and therapeutic methods are used to enhance bone health and assist in fracture healing while improving functional ability and reducing inflammation and bettering surgical results. [Lv C (2026); evidence level 1]
- However, persistent PTH elevation in advanced CKD-related SHPT may reflect more than isolated endocrine activity; available evidence suggests it integrates parathyroid-gland remodeling, receptor resistance, skeletal turnover, treatment refractoriness, and systemic CKD-MBD severity. [Liao MT (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Effects of macro- and micronutrient intake on bone mineral density, osteoporotic fracture risk, inflammation, and functional rehabilitation outcomes in orthopedic patients: a systematic review and meta-analysis.
- Pre-Parathyroidectomy PTH as an Integrated Biomarker of Glandular Remodeling and Skeletal Turnover in Secondary Hyperparathyroidism.